Navigating adalimumab biosimilars: an expert opinion

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort

(2023) Beatriz Gros et al.   United European Gastroenterology Journal

A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program

(2022) Kristin Karlsdottir et al.   Frontiers in Medicine

Real-World Outcomes Following Switching from Anti-TNF Reference Products to Biosimilars for the Treatment of Psoriasis

(2022) Rachel C. Ruda et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Patient knowledge about biosimilars and satisfaction with the education provided by rheumatologists or nurse specialists in a biosimilar multiswitch scenario – The perception study

(2022) Sabina Gall et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Overview of Humira® Biosimilars: Current European Landscape and Future Implications

(2021) Jill Coghlan et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis

(2021) Daniel E Furst et al.   RHEUMATOLOGY

Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study

(2021) Steven R. Feldman et al.   BIODRUGS

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?

(2021) Eduardo Mysler et al.   DRUGS

Classification and mitigation of negative injection experiences with biologic medications

(2020) Jennifer M. Fernandez et al.   Dermatologic Therapy

P505 Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience

(2020) D Rosembert et al.   Journal of Crohns & Colitis

PF-06410293: An Adalimumab Biosimilar

(2020) Arnold Lee et al.   BIODRUGS

Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review

(2020) Anja St Clair-Jones et al.   Rheumatology and Therapy

Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence

(2019) Salvatore Bellinvia et al.   BIODRUGS

AURIEL ‐PsO: A randomised, double‐blind Phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis

(2019) J. Hercogová et al.   BRITISH JOURNAL OF DERMATOLOGY

Impact of pain associated with the subcutaneous administration of adalimumab

(2019) Cristina Gely et al.   Gastroenterologia y Hepatologia

The Clinical Implications of Nocebo Effects for Biosimilar Therapy

(2019) Luana Colloca et al.   Frontiers in Pharmacology

Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases

(2019) Michaël Somers et al.   Journal of Crohns & Colitis

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

(2018) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

(2018) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Injectability as a function of viscosity and dosing materials for subcutaneous administration

(2018) Russell P. Watt et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Role of Buffers in Protein Formulations

(2017) Teddy J. Zbacnik et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study

(2017) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The road from development to approval: evaluating the body of evidence to confirm biosimilarity

(2017) Paul Declerck et al.   RHEUMATOLOGY

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis

(2017) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Subcutaneous Injection Volume of Biopharmaceuticals—Pushing the Boundaries

(2016) Roman Mathaes et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Underappreciated medication contraindication

(2010) Alicia J. Zbehlik et al.   ARTHRITIS CARE & RESEARCH